OPKO Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

OPKO Health wird ein Gewinn- und Umsatzwachstum von 49.5% bzw. 6.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 46.9% pro Jahr wachsen soll.

Wichtige Informationen

49.5%

Wachstumsrate der Gewinne

46.9%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	19.3%
Wachstumsrate der Einnahmen	6.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analysts Have Just Cut Their OPKO Health, Inc. (NASDAQ:OPK) Revenue Estimates By 14%

Feb 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:OPK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	743	-83	3	N/A	3
12/31/2025	715	-202	-35	-87	6
12/31/2024	705	-210	-130	-53	6
6/30/2024	716	-243	-86	-67	N/A
3/31/2024	800	-252	-59	-41	N/A
12/31/2023	863	-189	-44	-28	N/A
9/30/2023	867	-208	-41	-22	N/A
6/30/2023	868	-209	-110	-87	N/A
3/31/2023	913	-291	-120	-98	N/A
12/31/2022	1,004	-328	-120	-95	N/A
9/30/2022	1,220	-317	-94	-69	N/A
6/30/2022	1,426	-202	-28	-4	N/A
3/31/2022	1,559	-117	-36	-8	N/A
12/31/2021	1,775	-30	6	38	N/A
9/30/2021	1,868	76	46	78	N/A
6/30/2021	1,910	71	73	108	N/A
3/31/2021	1,769	121	72	109	N/A
12/31/2020	1,435	31	6	39	N/A
9/30/2020	1,165	-114	-72	-41	N/A
6/30/2020	966	-200	-151	-128	N/A
3/31/2020	891	-293	-182	-167	N/A
12/31/2019	902	-315	-185	-173	N/A
9/30/2019	899	-279	-173	-161	N/A
6/30/2019	920	-244	-181	-159	N/A
3/31/2019	958	-191	-147	-123	N/A
12/31/2018	990	-153	-137	-109	N/A
9/30/2018	929	-295	-112	-72	N/A
6/30/2018	926	-303	-131	-88	N/A
3/31/2018	955	-314	N/A	-94	N/A
12/31/2017	966	-305	N/A	-92	N/A
9/30/2017	1,081	-101	N/A	-64	N/A
6/30/2017	1,133	-80	N/A	-58	N/A
3/31/2017	1,197	-48	N/A	7	N/A
12/31/2016	1,117	-48	N/A	32	N/A
9/30/2016	1,222	-10	N/A	-8	N/A
6/30/2016	1,067	133	N/A	-7	N/A
3/31/2016	753	75	N/A	-84	N/A
12/31/2015	492	-30	N/A	164	N/A
9/30/2015	241	-85	N/A	149	N/A
6/30/2015	118	-262	N/A	159	N/A
3/31/2015	99	-244	N/A	171	N/A
12/31/2014	91	-172	N/A	-90	N/A
9/30/2014	86	-135	N/A	-92	N/A
6/30/2014	87	-147	N/A	-82	N/A
3/31/2014	87	-125	N/A	-64	N/A
12/31/2013	97	-115	N/A	-56	N/A
9/30/2013	92	-99	N/A	-35	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OPK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: OPK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: OPK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: OPKDie Einnahmen des Unternehmens (6.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: OPKDie Einnahmen des Unternehmens (6.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OPK in 3 Jahren voraussichtlich hoch sein wird

OPKO Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.30 loss, revenue downgraded

Price target decreased by 9.6% to US$3.92

Consensus EPS estimates fall by 16%

Consensus estimates of losses per share improve by 16%

Price target decreased by 11% to US$4.32

Consensus EPS estimates upgraded to US$0.25 loss

Recent updates

Not Enough To Keep OPKO Health Flying

Consensus EPS estimates upgraded to US$0.30 loss, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

OPKO Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

OPKO Health, Inc. (NasdaqGS:OPK) announces an Equity Buyback for $100 million worth of its shares.

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Price target decreased by 9.6% to US$3.92

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Chairman & CEO recently bought US$127k worth of stock

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

OPKO Health, Inc. announced delayed annual 10-K filing

New major risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

Chairman & CEO recently bought US$992k worth of stock

OPKO Health, Inc. to Report Q4, 2023 Results on Feb 27, 2024

OPKO Health, Inc., Annual General Meeting, Mar 28, 2024

Chairman & CEO recently bought US$1.5m worth of stock

President & Vice Chairman recently bought US$514k worth of stock

New minor risk - Profitability

OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Chairman & CEO recently bought US$1.3m worth of stock

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

OPKO Health, Inc. Presents Late-Breaking Clinical Data on RAYALDEE Extended-Release Calcifediol

OPKO Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is OPKO Health (NASDAQ:OPK) A Risky Investment?

Chairman & CEO recently bought US$176k worth of stock

Chairman & CEO recently bought US$1.2m worth of stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OPKO Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

New minor risk - Profitability

Consensus estimates of losses per share improve by 16%

Price target decreased by 11% to US$4.32

Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Consensus EPS estimates upgraded to US$0.25 loss

Chief Innovation Officer & Director recently bought US$541k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman & CEO recently bought US$264k worth of stock

Chairman & CEO recently bought US$1.2m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 36%

OPKO Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

Price target decreased to US$4.95

Chairman & CEO recently bought US$447k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

OPKO Health, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chairman & CEO recently bought US$182k worth of stock

Chairman & CEO recently bought US$133k worth of stock

Chairman & CEO recently bought US$413k worth of stock

OPKO Health: Assessing If Significant Potential Can Be Realized

Chairman & CEO recently bought US$214k worth of stock

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Chairman & CEO recently bought US$508k worth of stock

OPKO Health, Inc. Announces Leadership Changes for Bioreference Laboratories

Chairman & CEO recently bought US$802k worth of stock

OPKO Health, Inc. Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

OPKO Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term

OPKO Health, Inc., Annual General Meeting, Jul 14, 2022

Chairman & CEO recently bought US$1.1m worth of stock

First quarter 2022 earnings: EPS misses analyst expectations

OPKO Health, Inc. (NasdaqGS:OPK) acquired ModeX Therapeutics, Inc. for $300 million.

OPKO Health, Inc. to Report Q1, 2022 Results on May 09, 2022

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt